Peptides – shipping from Europe

Research Disclaimer: This article is intended for educational and informational purposes regarding the chemical and biochemical properties of research compounds. All information is provided strictly in a scientific context. This content does not constitute medical advice, nor does it promote the use of any compound for human or veterinary application. All compounds referenced are for laboratory research use only.

Glucagon-Like Peptide-1 (GLP-1) is a 30-amino acid incretin hormone produced by L-cells of the distal small intestine and colon in response to nutrient intake. Since its initial characterisation in the 1980s, GLP-1 has become one of the most extensively studied peptide hormones in metabolic biology, with its receptor — the GLP-1 receptor (GLP-1R) — established as a key node in glucose homeostasis, appetite regulation, and pancreatic function. GLP-1 receptor agonist peptides are synthetic compounds designed to interact with this receptor in experimental model systems.

Discovery of GLP-1

GLP-1 was identified in the mid-1980s as a product of the proglucagon gene — the same gene that encodes glucagon, but processed differently in intestinal L-cells than in pancreatic alpha cells. In L-cells, proglucagon is processed to yield GLP-1 (among other peptides), while in the pancreas, the same precursor yields glucagon.

Early research by scientists including Jens Juul Holst and Joel Habener established GLP-1’s role as an incretin — a gut-derived peptide that enhances insulin secretion in response to elevated blood glucose. This glucose-dependent mechanism attracted significant scientific interest, as it suggested a pathway for modulating insulin secretion without the risk of hypoglycaemia associated with non-glucose-dependent insulin secretagogues.

The subsequent decades of GLP-1 research have expanded well beyond its incretin function, identifying roles in gastric motility, satiety signalling, neuroprotection in cell models, and cardiovascular biology, making GLP-1 receptor biology one of the most active areas of metabolic research.

GLP-1 Receptor: Structure and Signalling

The GLP-1 receptor is a class B G protein-coupled receptor (GPCR), a family characterised by a long extracellular N-terminal domain that participates in ligand binding. GLP-1Rs are expressed in multiple tissue types, including pancreatic beta cells, the central nervous system, the cardiovascular system, and the gastrointestinal tract.

Upon ligand binding, the GLP-1R primarily couples to the Gs protein, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP) levels. In pancreatic beta cells, this cAMP signalling cascade enhances glucose-dependent insulin secretion — the core incretin mechanism. Secondary signalling pathways include activation of PKA and Epac (exchange protein activated by cAMP), which have downstream effects on cell survival, gene expression, and beta cell proliferation in experimental systems.

Semaglutide: Research Pharmacology

Semaglutide is a long-acting GLP-1 receptor agonist developed through modifications to the native GLP-1 sequence. The native GLP-1 peptide has a very short plasma half-life of approximately two minutes, due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and renal clearance. Semaglutide was engineered to resist DPP-4 cleavage and reduce renal filtration through structural modifications.

Key structural features of semaglutide include: substitution of the alanine at position 8 with alpha-aminoisobutyric acid to prevent DPP-4 cleavage; addition of a C18 fatty diacid chain linked via a short linker to lysine at position 26, enabling non-covalent binding to albumin and thereby extending plasma half-life; and several additional sequence modifications to optimise receptor affinity and pharmacokinetic properties.

GLP-1 Receptor Expression and Tissue Distribution

Incretin Research

The incretin function of GLP-1 — enhancement of glucose-stimulated insulin secretion — has been the subject of extensive research in both cell-based systems and animal models. Key findings from in vitro research include documentation of cAMP-mediated enhancement of insulin gene expression, promotion of insulin granule exocytosis in response to glucose, and inhibition of glucagon secretion from pancreatic alpha cells.

Research has also examined GLP-1’s effects on beta cell mass in rodent models, with studies reporting enhanced beta cell proliferation and reduced apoptosis in experimental settings. These findings have made the GLP-1 receptor a prominent research target in studies of pancreatic biology.

Central Nervous System Research

GLP-1 receptor expression in the central nervous system — particularly in hypothalamic nuclei involved in energy balance regulation — has been an active area of research. GLP-1 produced in the brain by a subset of neurons (distinct from peripheral GLP-1 from intestinal L-cells) is proposed to act as a neuropeptide modulating feeding behaviour, and GLP-1 receptor agonists have been studied in rodent models for their effects on food intake, body weight, and reward signalling.

Additionally, GLP-1Rs are expressed in brain regions associated with neuroprotection research, and preclinical studies have investigated GLP-1 receptor agonists in models of neurodegeneration, examining their effects on neuronal survival, neuroinflammation markers, and mitochondrial function in cell culture systems.

Laboratory Handling of GLP-1 Agonist Peptides

Note: GLP-1 receptor agonist research peptides are available from Aminopept for laboratory research use only. These compounds are not approved for human therapeutic use and are supplied exclusively for in-vitro and research purposes.

——————————————————————————————————-

GLP-1 is available in research-grade, lyophilized form from the Aminopept research catalogue. Supplied for laboratory and in-vitro research use only.

→ View GLP-1 in the research catalogue